Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use
the ONA take:
Early discharge following intensive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can reduce costs and use of intravenous antibiotics, according to a new study published online ahead of print in JAMA Oncology.
Because adults with AML or MDS typically remain hospitalized after induction or salvage chemotherapy, health care costs are driven up by the prolonged inpatient stay. Researchers sought to evaluate whether early discharge and outpatient management would be safe and reduce costs for these patients.
For the study, researchers from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle enrolled 146 patients with AML or MDS. Of those, 107 were discharged early and 29 served as inpatient controls. The early discharge patients were released from the hospital at the completion of chemotherapy and were provided with supportive care in the outpatient setting.
Results showed no significant difference in intensive care unit (ICU) days or transfusions per study day between the two treatment arms. Early discharge patients had more positive blood cultures than the inpatient controls but required fewer intravenous antibiotics. Costs were also lower for the early discharge group than for inpatients but had increased costs per inpatient day when readmitted for complications.
Outpatient Management Following Intensive AML or MDS Chemotherapy
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|